Heparin sodium Rx
Generic Name and Formulations:
Heparin sodium 1000, 5000, 10000units; per mL; IV or SC inj; preservative-free or preserved with benzyl alcohol.
Various generic manufacturers
Indications for Heparin sodium:
Adults and Children:
See full labeling. Individualize based on lab results and disease.
History of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis (HITT). Hypersensitivity to pork products. When blood coagulation testing is not feasible. Uncontrolled active bleeding state, except when due to disseminated intravascular coagulation.
IM use not recommended. Confirm choice of correct strength prior to administration. Monitor for any degree of thrombocytopenia; discontinue if platelet count falls <100000/mm3 or if recurrent thrombosis develops; evaluate for HIT and HITT; if needed, give alternative anticoagulant. Major bleeding or conditions with increased risk of hemorrhage (eg, bacterial endocarditis, severe hypertension, surgery, hemophilia, hereditary antithrombin III deficiency receiving concurrent antithrombin III therapy, ulcerative lesions, continuous GI tube drainage, menstruation, liver disease with impaired hemostasis). Monitor blood coagulation tests (discontinue if test is unduly prolonged or if hemorrhage occurs), platelets, hematocrit during therapy. Heparin resistance (monitor). History of allergy. Not interchangeable (unit-for-unit) with low molecular weight heparins. Women >60yrs of age. Elderly. Neonates/infants (gasping syndrome due to benzyl alcohol), pregnancy, nursing mothers: use preservative-free formulations.
Potentiated by anticoagulants (eg, dicumerol, warfarin), antiplatelets (eg, salicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, celecoxib, thienopyridines, dipyridamole, hydroxychloroquine, glycoprotein IIb/IIIa antagonists including abciximab, eptifibatide, tirofiban) and others; caution. Antagonized by digitalis, tetracyclines, nicotine, antihistamines, IV nitroglycerin. Potentiated by concurrent treatment with antithrombin III (human) in patients with hereditary antithrombin III deficiency; reduce heparin dose.
Hemorrhage, thrombocytopenia, HIT and HITT, inj site irritation, hypersensitivity reactions, increased aminotransferase levels.
Formerly known under the brand names Panheparin, Lipo-Hepin, Liquaemin.
Endocrinology Advisor Articles
- Update on Vitamin D and Calcium Supplements for Reducing Fracture Risk
- AAP Shares List of 5 Unnecessary Pediatric Tests and Procedures
- Severe Hypoglycemia Associated With Increased Mortality Risk in T2D
- Efficacy of CGM in Preterm Infants of Mothers With Diabetes
- SSRIs and SNRIs Linked to Type 2 Diabetes in Children, Adolescents
- High Grip Strength Associated With Lower Risk for Diabetes-Related AEs
- Statin Use for CVD Prevention Increases Diabetes Risk in Overweight Patients
- Optimal Timing of Gastric Bypass and Cholecystectomy When Both Procedures Clinically Indicated
- Does Asthma Contribute to Infertility?
- Short-Term Probiotics Increase Weight Loss in Overweight, Obesity